iamna 60/15 mikrogramu apvalkotās tabletes
sandoz d.d., slovenia - gestodenum, ethinylestradiolum - apvalkotā tablete - 60 µg/15µg
diflucan 2 mg/ml šķīdums infūzijām
pfizer limited, united kingdom - flukonazols - Šķīdums infūzijām - 2 mg/ml
voriconazole sciecure 200 mg pulveris infūziju šķīduma pagatavošanai
sciecure pharma ltd, united kingdom - vorikonazols - pulveris infūziju šķīduma pagatavošanai - 200 mg
polivy
roche registration gmbh - polatuzumab vedotin - limfomas b-Šūnu - antineoplastiski līdzekļi - polivy kopā ar bendamustine un rituksimabs ir norādīts ārstēšanai pieaugušiem pacientiem ar relapsed/ugunsizturīgi difūza liela b-šūnu limfoma (dlbcl), kas nav kandidātu hematopoētisko cilmes šūnu transplantācijas. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
idefirix
hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imūnsupresanti - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūts audzējs - antineoplastiski līdzekļi - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
skysona
bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - other nervous system drugs - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
furosemide basi 10 mg/ml šķīdums injekcijām/infūzijām
laboratorios basi - industria farmaceutica, s.a., portugal - furosemīds - Šķīdums injekcijām/infūzijām - 10 mg/ml
combivir
viiv healthcare bv - lamivudīnu, zidovudīns - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.